Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 2 1

Status

Terminated 1Completed 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Tumor-Agnostic 1Thoracic 1Gynecologic 1

Conditions

Neoplasms 2Ovarian Neoplasms 1Carcinoma, Non-Small-Cell Lung 1

Interventions

pembrolizumab 44Nivolumab 29Gemcitabine 28Paclitaxel 19Cisplatin 18Ipilimumab 15Carboplatin 14Cyclophosphamide 13Capecitabine 12Dexamethasone 10Bevacizumab 10cemiplimab 9Irinotecan 9Docetaxel 9Albumin-Bound Paclitaxel 9130-nm albumin-bound paclitaxel 9spartalizumab 8Pemetrexed 8Sorafenib 7Rituximab 7Cetuximab 7fludarabine 6Temozolomide 6Taxes 6Radiotherapy 6Leucovorin 6Fluorouracil 6Azacitidine 6Ascorbic Acid 6lenvatinib 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1/2 × Neoplasms × N-Ac-CHAVC-NH2 × Clear all
NCT00265057 2010-12-28

Study of ADH-1 Given Intravenously to Patients With Solid Tumors

Adherex Technologies, Inc.

Phase 1/2 Completed
GynecologicThoracic

Carcinoma, Non-Small-Cell Lung, Neoplasms, Ovarian Neoplasms

NCT00225550 2007-08-06

A Study of the Safety and Effects of ADH-1 Given Daily to Subjects With Solid Tumors

Adherex Technologies, Inc.

Phase 1/2 Terminated
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡